B-raf/RAF proto-oncogene serine/threonine-protein kinase · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14B-raf/RAF proto-oncogene serine/threonine-protein kinase shows late clinical disease relevance led by melanoma. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P04049. Start with melanoma, then reuse UniProt P04049 as the stable protein anchor across project notes and exports.
Start with melanoma, then reuse UniProt P04049 as the stable protein anchor across project notes and exports.
B-raf/RAF proto-oncogene serine/threonine-protein kinase shows late clinical disease relevance led by melanoma. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with melanoma because it currently carries late clinical support. Linked drugs include NAPORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRAF proto-oncogene serine/threonine-protein kinase
Review this target as B-raf/RAF proto-oncogene serine/threonine-protein kinase, mapped to UniProt P04049. ChEMBL maps the protein component as RAF proto-oncogene serine/threonine-protein kinase. Sequence length is 648 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats B-raf/RAF proto-oncogene serine/threonine-protein kinase as ChEMBL target CHEMBL3883317, mapped to UniProt P04049. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether B-raf/RAF proto-oncogene serine/threonine-protein kinase is the right protein anchor across sources, using UniProt P04049 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why melanoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | B-raf/RAF proto-oncogene serine/threonine-protein kinase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P04049 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | RAF proto-oncogene serine/threonine-protein kinase |
| UniProt Accession | P04049 |
| Component Type | Protein |
| Sequence Length | 648 aa |
RAF proto-oncogene serine/threonine-protein kinase
Review this target as B-raf/RAF proto-oncogene serine/threonine-protein kinase, mapped to UniProt P04049. ChEMBL maps the protein component as RAF proto-oncogene serine/threonine-protein kinase. Sequence length is 648 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
B-raf/RAF proto-oncogene serine/threonine-protein kinase shows late clinical disease relevance led by melanoma. 2 more disease programs remain visible in the same review block.
Start review with melanoma because it currently carries late clinical support. Linked drugs include NAPORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 13 | 0 | — |